Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
FIGHT-101
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
- NCT02393248 ↗
- Terminated
- Incyte Corporation
- Standard
We haven't built an HCP commentary report on FIGHT-101 (pemigatinib in advanced malignancies) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on FIGHT-101 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 11 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN
- Interventions
- Pemigatinib; Gemcitabine; Pembrolizumab; Docetaxel; Trastuzumab; Retifanlimab; Cisplatin
- Arms
- Part 1: Intermittent pemigatinib 1/2/4 mg QD · Experimental
- Part 1: Intermittent pemigatinib 6 mg QD · Experimental
- Part 1: Intermittent pemigatinib 9 mg QD · Experimental
- Part 1: Intermittent pemigatinib 13.5 mg QD · Experimental
- Part 1: Intermittent pemigatinib 20 mg QD · Experimental
- Part 1: Continuous pemigatinib 9 mg QD · Experimental
- Part 1: Continuous pemigatinib 13.5 mg QD · Experimental
- Part 1: Continuous pemigatinib 20 mg QD · Experimental
- Part 1: Continuous pemigatinib 7.5 mg BID · Experimental
- Part 1: Continuous pemigatinib 10 mg BID · Experimental
- Part 2: Intermittent pemigatinib 9 mg QD · Experimental
- Part 2: Intermittent pemigatinib 13.5 mg QD · Experimental
- Part 2: Continuous pemigatinib 9 mg QD · Experimental
- Part 2: Continuous pemigatinib 13.5 mg QD · Experimental
- Part 2: Continuous pemigatinib 20 mg QD · Experimental
- Part 3: Gem/Cis/intermittent pemigatinib 9 mg · Experimental
- Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg · Experimental
- Part 3: Tras/intermittent pemigatinib 13.5 mg · Experimental
- Part 3: Doc/intermittent pemigatinib 13.5 mg · Experimental
- Part 3: Pem/intermittent pemigatinib 9 mg · Experimental
- Part 3: Pem/intermittent pemigatinib 13.5 mg · Experimental
- Part 3: Pem/continuous pemigatinib 13.5 mg · Experimental
- Part 3: Ref/continuous pemigatinib 9 mg · Experimental
- Part 3: Ref/continuous pemigatinib 13.5 mg · Experimental
- Part 3: Ref/continuous pemigatinib 20 mg · Experimental
- Enrollment
- 201
- Primary outcomes
- Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
- Part 3: Number of Participants With Any TEAE
- E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
- EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
- Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
- Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2
- Sponsor
- Incyte Corporation
- Start
- Feb 27, 2015
- Primary completion
- Dec 17, 2021
- Results posted
- Yes
- Registry record
- NCT02393248 · updated Jan 6, 2023
Publications
linked from the registry- Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Feliz L, Lihou CF, Tian C, Silverman IM, Ji T, Saleh M. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol. 2022 May;33(5):522-533. doi: 10.1016/j.annonc.2022.02.001. Epub 2022 Feb 14. PubMed 35176457
- Gong X, Ji T, Liu X, Chen X, Yeleswaram S. Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies. Pharmacol Res Perspect. 2022 Feb;10(1):e00906. doi: 10.1002/prp2.906. PubMed 34951522